natgillin/translations-raw huggingface dataset:
125 doses (250 ml).
125 odm erki (250 ml).
125 IU/ml after reconstitution)
125 i.e./ml po rekonstituciji).
125 mcg
125 µg
125 mg retrievable
125 mg razpoložljivo po rekonstituciji.
125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg or
75 mg/18,75 mg/200 mg ali 125 mg/31,25 mg/200 mg ali 150 mg/37,5 mg/200 mg ali
125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Corbilta dosing should be carefully titrated for optimal clinical response.
125 mg/31,25 mg/200 mg ali 150 mg/37,5 mg/200 mg ali 200 mg/50 mg/200 mg), je treba za dosego optimalnega kliničnega odgovora odmerjanje zdravila Corbilta skrbno titrirati.
125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Stalevo dosing should be carefully titrated for optimal clinical response.
125 mg/31,25 mg/200 mg ali 150 mg/37,5 mg/200 mg ali 200 mg/50 mg/200 mg), je treba za dosego optimalnega kliničnega odgovora odmerjanje zdravila Stalevo skrbno titrirati.
125 mg/31.25 mg/200 mg or 175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg) tablets, Corbilta dosing should be carefully titrated for optimal clinical response.
150 mg/37,5 mg/200 mg ali 175 mg/43,75 mg/200 mg ali 200 mg/50 mg/200 mg), je treba za dosego optimalnega kliničnega odgovora odmerjanje zdravila Corbilta skrbno titrirati.
125 micrograms every two weeks showed a numerically greater treatment effect over the Plegridy every four weeks dosing regimen at year 1.
125 mikrogramov z režimom odmerjanja vsaka dva tedna pri 1. letu pokazalo številčno večji učinek zdravljenja kot zdravilo Plegridy z režimom odmerjanja vsake štiri tedne.
125 micrograms subcutaneously every 2 weeks were injection site erythema, influenza like illness, pyrexia, headache, myalgia, chills, injection site pain, asthenia, injection site pruritus, and arthralgia.
125 mikrogramov subkutano vsaka 2 tedna so bili eritem na mestu injiciranja, gripi podobna bolezen, pireksija, glavobol, mialgija, mrzlica, bolečina na mestu injiciranja, astenija, pruritus na mestu injiciranja in artralgija.
125 ml - 5years
125 ml – 5 leta
125 ml infusion bag
125 ml infuzijska vrečka
125 ml infusion bag.
Infuzijske vrečke s 125 ml.
125 ml per bag
125 ml/ vrečka
1250 mg/m2
1.000 mg/m2
1250 mg/m2
1.250 mg/m2
126 (4.1)
Faza II
126 (9 x 14)
126 (9 x14) tablet
126 (9x14), 490 (5 x (98x1)) tablets and in tablet containers of 100 and 200 tablets.
98 x 1, 126 (9x14), 490 (5 x (98x1)) tabletami in v vsebniku po 100 in 200 tablet.
1276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
1276 bolnikih (744 pri TAX 316 in 532 GEICAM 9805), ki so dobivali docetaksel v kombinaciji z doksorubicinom in ciklofosfamidom (predstavljeni so klinično pomembni, z zdravljenjem povezani, neţeleni učinki);
1276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
1276 bolnikih (744 pri TAX 316 in 532 GEICAM 9805), ki so prejemali docetaksel v kombinaciji z doksorubicinom in ciklofosfamidom (predstavljeni so klinično pomembni z zdravljenjem povezani neželeni učinki).
1276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
1276 bolnikih (744 v TAX 316 in 532 GEICAM 9805), ki so prejemali docetaksel v kombinaciji z doksorubicinom in ciklofosfamidom (predstavljeni so klinično pomembni z zdravljenjem povezani neželeni učinki).
128 days (docetaxel alone).
128 dnevi (samo docetaksel).
1296 ng•hr/mL (48%), respectively.
1296 ng•hr/ml (48 %).
12Discontinuation symptoms7, 12
poglavje 4.4)12 odtegnitveni simptomi7, 12
12x1 capsule (unit dose) +
12x1 kapsula (enkratni
13 (20.0%), p<0.0001
13 (20,0 %), p<0,0001
13 - Take the 30-gauge needle, take it out of its wrapping and place it firmly onto the tip (nozzle) of the syringe.
13 - Odstranite ovojnino z igle velikosti 30 in jo čvrsto pritrdite na konico (nastavek) brizge.
13 baits per square km over the areas where fox / raccoon dog density indexes were equal or less than 3 foxes / raccoon dogs seen per 10 km.
13 vab na kvadratni kilometer na področjih, kjer so indeksi gostote lisic/rakunastih psov enaki ali manjši kot tri videne lisice/rakunasti psi na 10 km.
13 baits per square km over the areas where fox /raccoon dog density indexes were equal or less than 3 foxes / raccoon dogs seen per 10 km.
13 vab na kvadratni kilometer na področjih, kjer so indeksi gostote lisic/rakunastih psov enaki ali manjši kot tri videne lisice/rakunasti psi na 10 km.
13 clicks
klikov
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 Povečanje telesne mase (kg) za ≥ 7 % glede na izhodiščno je bilo pri kratkotrajnem zdravljenju (srednje trajanje 22 dni) zelo pogosto (40,6 %), za ≥ 15 % pogosto (7,1 %) in za ≥ 25 % občasno (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % pogosto (7,1 %) in za ≥ 25% občasno (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % pogosto (7,1 %) in ≥ 25 % občasno (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % ter pogosto (7,1 %) in za ≥ 25 % občasno (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto ter pogosto (40,6 %), ≥ 15 % pogosto (7,1 %) in za ≥ 25% občasno (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
3S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % pogosto (7,1 %) in za ≥ 25 % občasno (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 %of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % pogosto (7,1 %) in za ≥ 25 % občasno (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15% of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % ter pogosto (7,1 %) in za ≥ 25 % občasno (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common and (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % pogosto (7,1 %) in za ≥ 25% občasno (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7% of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % ter pogosto (7,1 %) in za ≥ 25 % občasno (2,5 %) .
13 Following short term treatment (median duration 22 days), weight gain ≥ 7% of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % pogosto (7,1 %) in za ≥ 25 % občasno (2,5 %).
13 Following short term treatment (median duration 22 days), weight gain ≥ 7% of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % pogosto (7,1 %) in za ≥ 25 % občasno (2,5 %)..
13 Following short term treatment (median duration 22 days), weight gain ≥ 7% of baseline body weight (kg) was very common (40.6 %), ≥ 15% of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 S kratkoročnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), za ≥ 15 % pogosto (7,1 %) in za ≥ 25 % občasno (2,5 %).
13 mg/l perfused upper limb volume 10 mg/l perfused lower limb volume
13 mg/l volumna perfundirane zgornje okončine 10 mg/l volumna perfundirane spodnje okončine
13 mg/ml benzyl alcohol in water for injections.
13 mg/ml benzilalkohola v vodi za injekcije
13 SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEPORABLJENEGA ZDRAVILA ALI ODPADNIH SNOVI, ČE OBSTAJAJO
13 to less than 24
13 do manj kot 24
13% (w/w) ethanol 95% (see section 2) in water for injections.
13 % (m/m) 95 % etanola (glejte poglavje 2) v vodi za injekcije
13% (w/w) ethanol 95% in water for injections (see leaflet for further information) 6 ml (Fill 7.33 ml)
13 %(m/m) 95 % etanol v vodi za injekcije 6 ml (polnjenje 7,33 ml)
13% (w/w) ethanol 95% in water for injections Fill: 1.98 ml
13 % (m/m) 95 % etanol v vodi za injekcije Polnitev: 1,98 ml
13% * (N=150)
13 % * (n = 150)
13% had previous curative intent surgery or radiation and a rising PSA
13 % predhodno operacijo z namenom zdravljenja ali obsevanje in naraščajoč PSA.
13% of the emtricitabine dose was recovered in urine as three metabolites.
13% odmerka emtricitabina je iz urina izoliranega v obliki treh metabolitov.
13, 15 months
pri 13, 15 mesecih
13,811 females received control.
Cepivo Cervarix je prejelo 16.142 žensk, 13.811 žensk pa kontrolo.
13,970 and 2,970 ng•h/mL, respectively.
2.970 ng•h/ml.
13-week study, atrophic and degenerative changes occurred in reproductive organs of male mice; however these effects were reversible after a drug-free period (see section 4.6).
Pri mišjih samcih pa so se v 13-tedenski študiji pojavile atrofične in degenerative spremembe na reproduktivnih organih, ki so po prenehanju jemanja kapecitabina izginile (glejte poglavje 4.6).
13.
Pogosti
13.
Tableta.
13.0 months versus 7.6 months for those receiving CCR treatment, an improvement of 5.4 months with a stratified log-rank p-value of 0.0025.
CCR so sestavljali samo BSC (n=45), citarabin v majhnem odmerku skupaj z BSC (n=158) ali standardna intenzivna kemoterapija s citarabinom in antraciklinom skupaj z BSC (n=44).
13.0%
D,C,E
13.2 mg/m2/week) thus, 26% of patients received abatacept monotherapy in Period A. Of the
Med obdobjem A je abatacept kot samostojno zdravilo tako prejemalo 26% bolnikov.
13.3 mg
13,3°mg
13.3 mg/24 h
Rivastigm in 9,5 mg/24 h
13.3 mg/24 h transdermal patch is currently not available, this presentation may although be available from other marketing authorisation holders.
13,3 mg/24 h transdermalni obliž trenutno ni na razpolago, čeprav obstaja možnost, da imajo to jakost na razpolago drugi imetniki dovoljenja za zdravila.
13.4 mm x 7.3 mm, ellipse-shaped, normal convex, white film-coated tablets debossed “OZ 20” on one side and “G” on the other side.
13,4 mm x 7,3 mm, ovalne, obojestransko izbočene, bele filmsko obložene tablete z vtisnjeno oznako “OZ 20” na eni strani in “G” na drugi strani.
13.5 and 44.0-fold higher than the EC50 against wild type HIV, respectively.
44,0-krat večja kot EC50 proti divjemu tipu HIV.
13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups
13,5 primerov/1.000 bolnik-let, samo dieta 20,6 primerov/1.000 bolnik-let (p = 0,011), združeni skupini bolnikov na monoterapiji s sulfonilsečnino ali z insulinom
13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups
13,5 primerov/1.000 bolnikov-let, samo dieta – 20,6 primerov/1.000 bolnikov-let (p = 0,011), v primerjavi s skupinama s kombiniranim zdravljenjem s sulfonilsečnino in monoterapijo z insulinom – 18,9 primerov/1.000 bolnikov-let (p = 0,021);
13.5 mg once daily
13,5 mg enkrat na dan
13.5 mg twice daily
13,5 mg dvakrat na dan
13.6% (1.6-2.5 x ULN)
13,6% (1,6-2,5 x ULN)
13.7% of adult patients treated with Replagal in clinical trials have experienced idiosyncratic infusion related reactions.
13,7 % odraslih bolnikov, zdravljenih z zdravilom Replagal v kliničnih preskušanjih, je izkusilo idiosinkratične reakcije, povezane z infundiranjem.
13.8 (11.0, NR)
13,8 (11,0, ND)
13.8 (11.01 to 15.87)
13,8 (11,01 do 15,87)
13.BATCH NUMBER
ŠTEVILKA SERIJE
130
DOE
130 mg/daily])/ sofosbuvir (400 mg once daily)d
130 mg/dan])/ sofosbuvir (400 mg enkrat na dan)d
130 mg/m2
oksaliplatin
130 mg/m2 intravenous
130 mg/m2
130 tablets
130 tablet
130 tablets
175 tablet
130 units*.
130 enot*.
130 µg
15 µg
130 µg
20 µg
130, 150, 300 or 500 micrograms of the active substance darbepoetin alfa.
50, 60, 80, 100, 130, 150, 300 ali 500 mikrogramov zdravilne učinkovine darbepoetina alfa.
13013 Marseille France
13013 Marseille Francija
131 days
131 dni
1312 and 121 patients who received 100 mg/m2 and 75 mg/m2 of docetaxel as a single agent respectively.
1312 bolnikih, ki so v monoterapiji prejemali 100 mg/m2 docetaksela, 121 pa jih je prejemalo 75 mg/m2 docetaksela.
1312 and 121 patients who received 100 mg/m2 and 75 mg/m2 of docetaxel as a single agent respectively.
1312 bolnikih, ki so v monoterapiji prejemali 100 mg/m² docetaksela, 121 pa jih je prejemalo 75 mg/m².
1312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively.
1312 bolnikih, ki so v monoterapiji prejemali 100 mg/m² docetaksela, 121 pa jih je prejemalo 75 mg/m².
1312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively.
1312 bolnikih, ki so v monoterapiji prejemali 100 mg/m² docetaxela, 121 pa jih je prejemalo 75 mg/m².
1312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively.
1312 bolnikih, ki so v monoterapiji prejemali 100 mg/m² zdravila docetaksel, 121 pa jih je prejemalo 75 mg/m².
132 micrograms (36 million IU)/1.5 mL
132 mikrogramov (36 milijonov i.e.)/1,5 ml
132, 155, 156, 158, 168, 170, and 175.
107, 122, 132, 155, 156, 158, 168, 170 in 175.
132.13) in study 302.
71,4 ml (95-odstotni IZ: 10,57; 132,13) v študiji 302.
13342 Berlin Germany
13342 Berlin Nemčija
13353 Berlin Germany
13353 Berlin Nemčija
134 days
134 dni
13435 Berlin Germany
13435 Berlin Nemčija
135 (35.0)a,b
Tedni zdravljenja
135 (64.6%)a
0,29
135 (64.6%)a
136 (65%)a
135 g PRE-FILLED PEN
135 g NAPOLNJENI INJEKCIJSKI PERESNIK
135 g PRE-FILLED SYRINGE
135 g NAPOLNJENA INJEKCIJSKA BRIZGA
135 g VIAL
VIALA 135 g
13581 Berlin Germany
13581 Berlin Nemčija
136 (40)
n=337
136 [n.a.]
136 [ni na voljo]
136.0 mg/tablet
136,0 mg/tableto
136mL p=0.048 (1, 270)
(1, 270)
137.5 ml (or 150 ml)*
137,5 ml (ali 150 ml)
137.5 ml (or 150 ml)*
137.5 ml (ali 150 ml)
1381 CP Weesp The Netherlands
1381 CP Weesp Nizozemska
13C and urea are harmless naturally occurring substances which are found in your body.
13C in sečnina sta nenevarni, naravno dani snovi, ki se nahajata tudi v vašem telesu.
13C-urea
13C-sečnina
13C-urea
13C-sečnine
13Following short term treatment (median duration 22 days), weight gain ≥ 7% of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %).
13 S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % ter pogosto (7,1 %) in za ≥ 25 % občasno (2,5 %).
14 %, for dose modification 18 % vs.
14 % bolnikov, odmerek pa prilagodili pri 18 % oz.
14 (38.9%)a
14 (38.,%)a
14 - 28 - 56 - 84 - 98 tablets:
14 - 28 - 56 - 84 - 98 tablet:
14 - 28 - 56 - 84 - 98 tablets: Mon
14 - 28 - 56 - 84 - 98 tablet:
14 - 28 - 56 - 98 tablets:
14 - 28 - 56 - 98 tablet:
14 - Dispose of the vial and the remaining unused portion of the solution into the disposal unit.
14 - Vialo in neporabljen del raztopine zavrzite v posodo za odpadke.
14 August 2015
14. avgust 2015
14 capsules
14 trdih kapsul
14 capsules
oblika
14 cases of insomnia were reviewed and these also included positive dechallenge experience.
Obravnavanih je bilo 14 primerov nespečnosti in tudi ti so vključevali pozitiven odziv na prenehanje uporabe.
14 cases of nightmare were reviewed in the current PSUR, which included cases of both positive dechallenge and rechallenge.
V trenutnem poročilu PSUR je bilo obravnavanih 14 primerov nočnih mor, ki so vključevali primere s pozitivnim odzivom na prenehanje uporabe in tudi na ponovno uporabo.
14 clicks
klikov
14 February 1996 / 2 February 2006
Datum prve odobritve: 14. februar 1996
14 film coated tablets 28 film coated tablets 84 film coated tablets
14 filmsko obloženih tablet 28 filmsko obloženih tablet 84 filmsko obloženih tablet
14 film--coated tablets
14 filmsko obloženih tablet.
14 film-coated tablets
14 filmsko obloženih tablet 28 filmsko obloženih tablet
14 film-coated tablets
14 filmsko obloženih tablet.
14 film-coated tablets
14 x 1 filmsko obložena tableta
14 film-coated tablets
7 filmsko obloženih tablet 14 filmsko obloženih tablet
14 film-coated tablets (calendar blister)
14 filmsko obloženih tablet (koledarsko pakiranje)
14 film-coated tablets 7 film-coated tablets
14 filmsko obloženih tablet 7 filmsko obloženih tablet
14 film-coated tablets 7 film-coated tablets
7 filmsko obloženih tablet.
14 film-coated tablets in calendar blisters
14 filmsko obloženih tablet v koledarskih pretisnih omotih
14 film-coated tablets of Vimpat 100 mg 14 film-coated tablets of Vimpat 150 mg 14 film-coated tablets of Vimpat 200 mg
14 filmsko obloženih tablet zdravila Vimpat 100 mg 14 filmsko obloženih tablet zdravila Vimpat 150 mg 14 filmsko obloženih tablet zdravila Vimpat 200 mg
14 Film-coated tablets.
14 filmsko obložena tableta
14 g/dl (8.7 mmol/l), ESAs are not indicated for use in this patient population.
Uporaba ESA v tej populaciji bolnikov ni indicirana.
14 gastro-resistant tablets
14 gastrorezistentnih tablet
14 hard capsules (in two aluminum blisters), with each capsule pocket connected to a pocket with desiccant.
14 trdih kapsul (v dveh aluminijastih pretisnih omotih), pri čemer je ţepek vsake kapsule povezan z ţepkom s sušilnim sredstvom.
14 hard capsules 56 hard capsules 196 hard capsules
14 trdih kapsul 56 trdih kapsul 196 trdih kapsul
14 hard capsules 56 hard capsules 70 hard capsules 84 hard capsules 100 hard capsules
14 trdih kapsul 56 trdih kapsul 70 trdih kapsul 84 trdih kapsul 100 trdih kapsul
14 hard gastro-resistant capsules 28 hard gastro-resistant capsules 84 hard gastro-resistant capsules 98 hard gastro-resistant capsules 28 x 1 hard gastro-resistant capsules
14 trdih gastrorezistentnih kapsul 28 trdih gastrorezistentnih kapsul 84 trdih gastrorezistentnih kapsul 98 trdih gastrorezistentnih kapsul 28 x 1 trda gastrorezistentna kapsula
14 IU
14 i.e.
14 kg to less than 25 kg
14 kg do manj kot25 kg
14 mg orally once daily
14 mg peroralno enkrat na dan
14 mg per kilogram body weight for adult patients not receiving regular blood transfusions,
14 mg na kilogram telesne mase za odrasle bolnike, ki ne prejemajo rednih transfuzij krvi,
14 orodispersible tablets
14 orodisperzibilnih tablet
14 patients required invasive ventilation support (intubation or tracheostomy) at baseline (one had a brief period of non-invasive ventilation at baseline before transfer).
14 bolnikov je potrebovalo invazivno ventilacijsko podporo (intubacija ali traheostomija) ob izhodišču (eden je imel kratko obdobje neinvazivne ventilacije ob izhodišču pred transferjem);
14 prolonged-release tablets
14 tablet s podaljšanim sproščanjem
14 prolonged-release tablets - EU/1/07/395/065 - CLEAR 28 prolonged-release tablets - EU/1/07/395/001 - CLEAR 30 prolonged-release tablets - EU/1/07/395/002 - CLEAR 49 prolonged-release tablets - EU/1/07/395/003 - CLEAR 56 prolonged-release tablets - EU/1/07/395/004 - CLEAR 98 prolonged-release tablets - EU/1/07/395/005 - CLEAR
14 tablet s podaljšanim sproščanjem - EU/1/07/395/065 – PROZOREN PRETISNI OMOT 28 tablet s podaljšanim sproščanjem - EU/1/07/395/001 - PROZOREN PRETISNI OMOT 30 tablet s podaljšanim sproščanjem - EU/1/07/395/002 - PROZOREN PRETISNI OMOT 49 tablet s podaljšanim sproščanjem - EU/1/07/395/003 - PROZOREN PRETISNI OMOT 56 tablet s podaljšanim sproščanjem - EU/1/07/395/004 - PROZOREN PRETISNI OMOT 98 tablet s podaljšanim sproščanjem - EU/1/07/395/005 - PROZOREN PRETISNI OMOT
14 prolonged-release tablets - EU/1/07/395/066 - WHITE 28 prolonged-release tablets - EU/1/07/395/021 - WHITE 30 prolonged-release tablets - EU/1/07/395/022 - WHITE 49 prolonged-release tablets - EU/1/07/395/023 - WHITE 56 prolonged-release tablets - EU/1/07/395/024 - WHITE 98 prolonged-release tablets - EU/1/07/395/025 - WHITE
14 tablet s podaljšanim sproščanjem - EU/1/07/395/066 – BEL PRETISNI OMOT 28 tablet s podaljšanim sproščanjem - EU/1/07/395/021 - BEL PRETISNI OMOT 30 tablet s podaljšanim sproščanjem - EU/1/07/395/022 - BEL PRETISNI OMOT 49 tablet s podaljšanim sproščanjem - EU/1/07/395/023 - BEL PRETISNI OMOT 56 tablet s podaljšanim sproščanjem - EU/1/07/395/024 - BEL PRETISNI OMOT 98 tablet s podaljšanim sproščanjem - EU/1/07/395/025 – BEL PRETISNI OMOT
14 prolonged-release tablets - EU/1/07/395/067 28 prolonged-release tablets - EU/1/07/395/041 49 prolonged-release tablets - EU/1/07/395/042 56 prolonged-release tablets - EU/1/07/395/043 98 prolonged-release tablets - EU/1/07/395/044
14 tablet s podaljšanim sproščanjem EU/1/07/395/067 28 tablet s podaljšanim sproščanjem EU/1/07/395/041 49 tablet s podaljšanim sproščanjem EU/1/07/395/042 56 tablet s podaljšanim sproščanjem EU/1/07/395/043 98 tablet s podaljšanim sproščanjem EU/1/07/395/044